Renal Cell Carcinoma: A Review of 72 Cases.
- Author:
Rhee Hong WOO
1
;
Su Kil LIM
Author Information
1. Catholic University Medical College, Seoul, Korea.
- Publication Type:Original Article
- Keywords:
renal cell carcinoma;
prognosis
- MeSH:
Alkaline Phosphatase;
Angiography;
Carcinoma, Renal Cell*;
Drug Therapy;
Female;
Flank Pain;
Follow-Up Studies;
Gait;
Hematuria;
Humans;
Immunotherapy;
Incidence;
Liver;
Liver Function Tests;
Lung;
Lymph Nodes;
Male;
Neoplasm Metastasis;
Nephrectomy;
Prognosis;
Retrospective Studies;
Tomography, X-Ray Computed;
Ultrasonography;
Urology
- From:Korean Journal of Urology
1989;30(3):326-332
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
A clinical observation was done in 72 patients with renal cell carcinoma admitted to Department of Urology, St. Mary's Hospital, Catholic University Medical College from Jan. 1980 to Jun. 1988 retrospectively. There were 52 men and 20 women, giving a ratio of 2.6 to 1, with the highest incidence in the sixth to seventh decades (66%). The most common symptom and sign were hematuria, flank pain and palpable mass in orders, but classic symptom triad of renal cell carcinoma was present in only 11% of the patients. Symptoms secondary to metastasis were only initial presentations in more than half of the patients with stage IV disease, initially 11% (12 pts.) of all the patients with renal cell carcinoma. CT scan showed a high diagnostic accuracy (78%) as compared to pathologic examination. So recently angiography is not done routinely. In one patient, tumor was not detected by CT scan, but by ultrasonography and angiography. Liver scan is not indicated unless there are 2 or more abnormal values among liver function test including alkaline phosphatase, GOT and GPT. Bone metastasis is not correlated with the elevation of alkaline phosphatase and bone scan is indicated only when bone pain and/or gait disturbance are present. Radical nephrectomy is the choice of treatment and adjunctive therapy including. irradiation, chemotherapy, hormone therapy and immunotherapy were not effective. The majority of distant metastasis (86%) occurred within the first 2 years following nephrectomy and metastatic sites were lung, lymph nodes, liver and bone in orders. Of the 72 patients, it was possible for 36 patients to follow up more than 3 years. Patients with stage 1 disease showed 90%. (9/10) 3 year survival and there were no significant differences in 3 year survival between stage II (50%) and stage III (44%) disease. No patients with stage IV disease survived more than 3 years.
